Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Atypical antipsychotics (AAPs) & Cardiovascular diseases (CVD)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Atypical antipsychotics (AAPs) have been associated with an increased risk of cardiovascular diseases (CVD). Several studies have highlighted the prevalence of CVD as a secondary effect of AAP use in patients with schizophrenia.
Zhang et al. 2021m Front Psychiatry 12: 640244

Additionally, Atypical Antipsychotics (AAPs) have been linked to metabolic effects such as insulin resistance, weight gain, and an increased risk of diabetes and Cardiovascular diseases (CVD)
Burghardt et al. 2018 Progress in Neuro-Psychopharmacology and Biological Psychiatry 83: 55-63

At least 40% of patients taking [Atypical Antipsyc…

References (Sources)

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls
Goff et al. 2005 Schizophr Res 80(1): 45-53
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
Daumit et al. 2008 Schizophr Res 105(1–3): 175-87
Cardiovascular Risk of Concomitant Use of Atypical Antipsychotics and Stimulants Among Commercially Insured Youth in the United States
Zhang et al. 2021m Front Psychiatry 12: 640244
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1
Meyer et al. 2008 Schizophr Res 101(1-3): 273-86
Interaction between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort
Flowers et al. 2016 Pharmacotherapy. doi: 10.1002/phar.1890
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III
McEvoy et al. 2005 Schizophr Res 80 (1): 19-32
Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report
National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A 2002 Circulation 106(25): 3143-4213

AI Chat

7/1/2026

Chat with our artificial intelligence: